Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells

Cancer Research

Volumn 67, Issue 1, 2007, Pages 227-236

  Kurooka, Masayuki ^a   Kaneda, Yasufumi ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CELL PROLIFERATION; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENDAI VIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; ULTRAVIOLET RADIATION; VIRUS ACTIVATION; VIRUS REPLICATION;

ANIMALS; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; SENDAI VIRUS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VIRUS INACTIVATION; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846432377     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1615     Document Type: Article

References (44)

1. Steinman HM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004;305:197-200.
2. Blattaman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
3. Pawelec G. Immunotherapy and immunoselection-tumor escape as the final hurdle. FEBS Lett 2004;567:63-6.
4. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54.
5. Staveley-O'Carrol K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the cause of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
7. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005;53PA:307-32.
8. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003;4:599-602.
9. Kaneda Y, Nakajima T, Nishikawa T, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002;6:219-26.
10. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005;7:1044-52.
11. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006;13:194-202.
12. Hiraoka K, Yamamoto S, Otsuru S, et al. Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 2004;173:4297-307.
13. Mima H, Yamamoto S, Ito M, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006;5:1021-8.
14. Worgall S, Busch A, Rivara M, et al. Modification to Capsid of the Adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 2004;78:2572-80.
15. Kaufman HL, DeRaffele G, Mitcham J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005;115:1903-12.
16. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003;7:755-64.
17. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW, Jr., et al. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. Mol Ther 2006;13:183-93.
18. Leitner WW, Hwang LN, deVeer MJ, et al Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-9.
19. Lu W, Zheng S, Li XF, Huang JJ, Zheng X Li 7. Intratumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol 2004;10:3634-8.
20. Bosma MJ, Carroll AM. The SCID mouse: definition, characterization, and potential uses. Annu Rev Immunol 1991;9:323-50.
21. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004;4:489-511.
22. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-strand RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-7.
23. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-22.
24. + immunoregulatory cells. J Immunol 2001;167:1137-40.
25. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
26. Shevach EM. Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423-49.
27. + T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
28. + Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005;115:313-25.
29. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
30. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
31. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-99.
32. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
33. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
34. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91.
35. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
36. + regulatory T cell proliferation. J Exp Med 2005;202:919-29.
37. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986;324:73-6.
38. Teranishi T, Hirano T, Arima N, Onoue K. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell replacing factor (TRF)-like factor(s). J Immunol 1982;128:1903-8.
39. Hirano T. Interleukin 6 and its receptor. Ten years later. Int Rev Immunol 1998;16:249-84.
40. + regulatory T cells. Hum Immunol 2005;66:460-8.
41. Lopez CB, Garcia-Sastre A, Williams BR, Moran TM. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 2003;187:1126-36.
42. Lopez CB, Moltedo B, Alexopoulou L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA virus. J Immunol 2004;173:6882-9.
43. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through 0X40 ligand and type I IFNs. J Immunol 2004;172:4253-9.
44. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. In: Huang L, Hung MC, Wagner E, editors. Non-viral vectors for gene therapy. London: Elsevier Academic Press: 2005. p. 307-32.